Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Ranibizumab demonstrated a clear clinical advantage over laser photocoagulation in improving visual acuity, with significant gains reported in both the RESTORE and DRCR.net trials. The average increase in visual acuity was 6.1 letters for ranibizumab monotherapy and 9 letters for ranibizumab plus laser photocoagulation, compared to only 0.8 letters for laser photocoagulation alone (p<0.001). This evidence supports a strong therapeutic impact, although the lack of long-term follow-up data limits the robustness of the findings.
Cost effectiveness
The cost-effectiveness analysis indicated an ICER of £19,075 per QALY gained for ranibizumab monotherapy compared to laser photocoagulation. While this is within acceptable thresholds, the ICER is sensitive to various assumptions, and the model’s reliance on a patient access scheme adds uncertainty regarding its long-term economic viability.
Quality of life
The HRQoL data from the RESTORE trial indicated positive changes in vision-related quality of life, as measured by the NEI VFQ-25, with statistically significant improvements in composite scores. However, the benefits were not uniformly observed across all subscales, particularly in areas like dependency and driving, which suggests moderate but meaningful improvements in quality of life.
Supporting Domains
Safety and Adverse Effects
Ranibizumab has a favorable safety profile, with adverse effects primarily limited to ocular events. The trials did not report significant differences in the frequency of adverse events between treatment arms, indicating that ranibizumab is well tolerated compared to existing therapies.
Comparator Selection
The manufacturer did not include a comparison with bevacizumab, which is a relevant comparator listed in the appraisal scope. This omission raises concerns about the completeness of the evidence base, although the focus on laser photocoagulation aligns with current clinical practice.
Patient Population and Subgroups
The trials included a diverse patient population with diabetic macular oedema, and subgroup analyses indicated that ranibizumab may be particularly effective in patients with thicker retinas. This suggests broad applicability of the findings, although some concerns about generalizability to the wider population remain.
Care Pathway Integration
Ranibizumab can be integrated into existing care pathways with minimal disruption, as it is administered on an outpatient basis and aligns with current treatment practices for diabetic macular oedema. Some adjustments may be needed for monitoring and follow-up, but these are manageable.
Resource Use and Cost Implications
The economic model indicates a notable cost burden associated with ranibizumab treatment, particularly when considering the need for multiple injections and monitoring visits. While the patient access scheme mitigates some costs, the overall resource implications remain significant.
Evidence Quality and Robustness
The evidence base is supported by multiple high-quality RCTs, including RESTORE and DRCR.net, which were deemed methodologically sound. However, the lack of long-term follow-up data introduces some uncertainty regarding the durability of treatment effects.
Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the long-term effectiveness and cost-effectiveness of ranibizumab, particularly in relation to the need for ongoing treatment and the impact of glycaemic control on outcomes. These uncertainties could affect the broader implementation of the therapy.
